In another aspect, there is provided a use of the compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one in the preparation of a medicament for the curative treatment of a liver cancer.

In yet another aspect, there is provided a use of the compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one in the preparation of a medicament for the inhibition of proliferation and/or activation of cells responsible for the production of collagen fibers and/or responsible for the production of the extracellular matrix, and wherein the medicament is for the treatment or prevention of fibrotic diseases, wherein the fibrotic disease is not liver fibrosis, or for the treatment or prevention of a tyrosine kinase related cancer.

In still another aspect, there is provided a use of the compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one in the preparation of a medicament for promoting apoptosis of cells responsible for the production of collagen fibers and/or responsible for the production of the extracellular matrix, and wherein the medicament is for the treatment or prevention of fibrotic diseases, wherein the fibrotic disease is not liver fibrosis, or for the treatment or prevention of a tyrosine kinase related cancer.

DESCRIPTION OF THE FIGURES AND TABLES

Abbreviations used in the figures, in the tables, and in the text:

- Col1a1 = collagen, type I, alpha 1
- Col4a1 = collagen, type 4, alpha 1
- Cpm = counts per minute

7. The use according to claim 6, wherein the liver cancer is a hepatocellular carcinoma.

8. Use of a compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one in the preparation of a medicament for the inhibition of proliferation and/or activation of cells responsible for the production of collagen fibers and/or responsible for the production of the extracellular matrix, and wherein the medicament is for the treatment or prevention of fibrotic diseases, wherein the fibrotic disease is not liver fibrosis, or for the treatment or prevention of a tyrosine kinase related cancer.

9. Use of a compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one in the preparation of a medicament for promoting apoptosis of cells responsible for the production of collagen fibers and/or responsible for the production of the extracellular matrix, and wherein the medicament is for the treatment or prevention of fibrotic diseases, wherein the fibrotic disease is not liver fibrosis, or for the treatment or prevention of a tyrosine kinase related cancer.